Literature DB >> 6254685

Failure of intensive combination therapy (cyclophosphamide, adriamycin, 5-fluorouracil) to control adenocarcinoma or large-cell anaplastic carcinoma of lung.

R E Taylor, I E Smith, H T Ford, B M Bryant, A J Casey, J F Smyth.   

Abstract

Eleven patients with advanced adenocarcinoma of lung and six patients with large cell anaplastic carcinoma of lung were treated with combination chemotherapy using cyclophosphamide 1 g/m2 i.v., adriamycin 30 mg/m2 and 5-FU 500 mg/m2 i.v. on days 1 and 8, of a 28 day cycle. In neither group did any patient achieve a complete remission; 1 patient achieved a partial response in each group, and the rest showed no evidence of response. The duration of survival of the responding patients in each group was not significantly longer than those of the non-responders. Toxicity and side effects were considerable in all patients. This study demonstrates that these tumour types are refractory to this form of intensive combination chemotherapy. A literature review suggests that other forms of combination chemotherapy are usually equally ineffective.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6254685     DOI: 10.1007/bf00255273

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  13 in total

1.  Combination chemotherapy with methyl-CCNU, 5-fluorouracil, and vincristine in adenocarcinoma and large cell carcinoma of the lung.

Authors:  A M Bernath; M H Cohen; D C Ihde; B E Fossieck; M J Matthews; J D Minna
Journal:  Cancer Treat Rep       Date:  1976-09

2.  Combination chemotherapy of advanced lung cancer: a randomized trial.

Authors:  H H Hansen; O S Selawry; R Simon; D T Carr; C E van Wyk; R D Tucker; R Sealy
Journal:  Cancer       Date:  1976-12       Impact factor: 6.860

Review 3.  Monochemotherapy of bronchogenic carcinoma withs special reference to cell type.

Authors:  O S Selawry
Journal:  Cancer Chemother Rep 3       Date:  1973-03

4.  Chemotherapy for adenocarcinoma of the lung with 5-fluorouracil, cyclophosphamide, and CCNU (FCC).

Authors:  A Y Bedikian; R Staab; R Livingston; M Valdivieso; M A Burgess; G P Bodey
Journal:  Cancer       Date:  1979-09       Impact factor: 6.860

5.  MACC chemotherapy for adenocarcinoma and epidermoid carcinoma of the lung: low response rate in a Cooperative Group Study. Eastern Cooperative Oncology Group.

Authors:  S E Vogl; C R Mehta; M H Cohen
Journal:  Cancer       Date:  1979-09       Impact factor: 6.860

6.  Cyclophosphamide and CCNU in the treatment of inoperable small cell carcinoma and adenocarcinoma of the lung.

Authors:  J H Edmonson; S W Lagakos; O S Selawry; C P Perlia; J M Bennett; F M Muggia; G Wampler; H S Brodovsky; J Horton; J Colsky; E G Mansour; R Creech; L Stolbach; E M Greenspan; M Levitt; L Israel; E Z Ezdinli; P P Carbone
Journal:  Cancer Treat Rep       Date:  1976-07

7.  Results of two sequential chemotherapy studies in WHO Types I, III and IV lung cancer: cyclophosphamide-5-fluorouracil (CF) and cyclophosphamide-5-fluorouracil-adriamycin (CAF).

Authors:  A Brugarolas; A J Lacave; A Ribas; J M Buesa; M T Garcia Miralles
Journal:  Eur J Cancer       Date:  1979-03       Impact factor: 9.162

8.  5-Fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy for adenocarcinoma of the lung.

Authors:  T P Butler; J S MacDonald; F P Smith; L F Smith; P V Woolley; P S Schein
Journal:  Cancer       Date:  1979-04       Impact factor: 6.860

9.  Combination chemotherapy with cyclophosphamide, adriamycin, intermediate dose methotrexate, and folinic acid rescue (CAMF) in advanced lung cancer.

Authors:  F Robert; G Omura; A A Bartolucci
Journal:  Cancer       Date:  1980-01-01       Impact factor: 6.860

10.  Chemotherapy for bronchogenic carcinoma. Methotrexate, doxorubicin, cyclophosphamide, and lomustine.

Authors:  P A Chahinian; D J Arnold; J M Cohen; D P Purpora; I S Jaffrey; A S Teirstein; P A Kirschner; J F Holland
Journal:  JAMA       Date:  1977-05-30       Impact factor: 56.272

View more
  5 in total

1.  Cyclic combination chemotherapy in advanced adenocarcinoma of the lung: comparison of two FAM schedules.

Authors:  W K Lam; S Y So; M Ip; D Y Yu
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 2.  Combination chemotherapy for advanced adenocarcinoma of the lung. A review.

Authors:  J B Sørensen; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  Stimulation of resistance of immunocompromised mice by a muramyl dipeptide analog.

Authors:  Y Osada; M Mitsuyama; K Matsumoto; T Une; T Otani; H Ogawa; K Nomoto
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

4.  5-fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy in advanced adenocarcinoma of the lung: comparison of two dosage schedules.

Authors:  W K Lam; S Y So; T M Kung; M K Sham; M Ip
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

5.  Experimental combination and single-agent chemotherapy in human lung-tumour xenografts.

Authors:  A J Shorthouse; J M Jones; G G Steel; M J Peckham
Journal:  Br J Cancer       Date:  1982-07       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.